Valeo Pharma announced today that it entered into a commercialization and supply agreement with Novartis Canada for its asthma therapies. Montreal-based Valeo’s deal is to offer Canadian commercialization efforts for two asthma therapies: Enerzair Breezhaler (indacaterol as acetate, glycopyrronium as bromide and mometasone furoate, and Atectura Breezhaler (indacaterol as acetate and mometasone fuorate). Under the […]
Pharmaceuticals
Diomics, Bonne Santé Group enter strategic alliance
Diomics and Bonne Santé Group announced today that they entered into a strategic alliance to develop a line of Diocare products. San Diego-based Diomics and Miami-based Bonne Santé Group, which operated through its Bonne Santé Natural Manufacturing division, entered the agreement in an effor tto develop, launch and distribute the Diocare products formulated to address […]
Vaxess Technologies raises $2M for its silk-based vaccine delivery through the skin
Vaxess Technologies today filed an SEC Form D to confirm the sale of $2 million in debt, options, warrants or other rights to buy securities. According to the filing, three investors contributed to the new notice offering, which made its first sale on Monday, March 22, 2021, before reaching its total offering amount of $2 […]
ACG launches NTone, TSafe range of capsules
ACG announced today that it launched its new ACGcaps NTone and ACGcaps TSafe range of capsules for the nutraceutical market. Mumbai, India-based ACG’s NTone portfolio includes naturally colored capsules with no e-number. THe colors used are safe and non-toxic and contain no artificial ingredients, while the product shelf life is unchanged compared to synthetic-colored capsules, […]
FDA approves oral multiple sclerosis treatment from J&J’s Janssen unit
Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical announced today that it received FDA approval for its Ponvory treatment. Ponvory (ponesimod) is a once-daily, oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator for treating adults with relapsing forms of multiple sclerosis (MS). It’s areas of treatment include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, […]
Oramed forms joint venture to develop oral COVID-19 vaccines with POD delivery tech
Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it is forming a joint venture to develop novel oral COVID-19 vaccines. New York-based Oramed entered into definitive agreements to form Oravax Medical, which is based on Oramed’s proprietary POD (protein oral delivery) technology and Premas Biotech’s novel vaccine technology, according to a news release. Oravax’s COVID-19 vaccine candidate […]
How Lyra Therapeutics is advancing rhinosinusitis treatment
With the use of anti-inflammatory drugs constituting the standard of care for treating rhinosinusitis, Lyra Therapeutics sees an opportunity. Whatever treatments are out there for the disease in which cavities around the nasal passages are inflamed, they leave room for improvement. “We focused on chronic rhinosinusitis because it’s an area that has been ignored,” Lyra […]
Frequency Therapeutics drug shows promise in restoring hearing in small study
Frequency Therapeutics (Woburn, Mass.) recently announced data related to its experimental FX-322 drug. The small Phase 1/2 study, which was published in Otology & Neurotology, found hearing improvements in adults with age-related sensorineural hearing loss. At present, there are no FDA-approved drugs for preventing or restoring such hearing loss, although administering steroids can facilitate recovery […]
Eyenovia touts study of pupil dilation treatment
Eyenovia (NSDQ:EYEN) today announced positive results from a study of its microdose array print (MAP) pupil dilation technology. Study data, published in Therapeutic Delivery, revealed pooled results from two prospective, double-masked, controlled, cross-over superiority Phase 3 studies. Those results concluded that a micro-dosed fixed-combination of tropicamide 1% and phenylephrine 2.5% for pupil dilation (mydriasis) is safe and […]
Oramed reaches 25% randomization in oral insulin trial, expects topline results in 2022
Oramed Pharmaceuticals (NSDQ:ORMP) announced that it reached 25% randomization in the enrollment for its oral insulin capsule trial. New York-based Oramed’s Phase 3 ORA-D-013-1 study for the ORMD-0801 oral insulin capsule for the treatment of Type 2 diabetes has planned for 675 patients overall, reaching a quarter of that mark in enrollment so far with […]
